Are Phase I studies becoming too complex?
Medrio’s latest report with ISR Market Research reveals striking data.
From 2018-2023, the number of subjects in Phase I trials decreased by 50%, yet variables affecting trial complexity increased by nearly 35%.
Additionally, In the last five years, Medrio’s clients saw a:
🔷16.2% increase in the average number of forms
🔷10.9% increase in the number of data points
🔷21.1% increase in the number of form rules
To quote Medrio CEO Nicole Latimer, “Complexity is relative. But if you simply look at the volume of data, we’ve seen a huge increase in variables within phase I trials.”
Find out what’s driving these new complexities in Phase I trials and get exclusive guidance from early phase experts on how to navigate them.
This report includes the research results and industry expert insights that explore the “why” behind the data. It highlights and discusses three major findings:
-
How increasing variables affect early phase research
-
How sponsors navigate the pressure to move quickly
-
Why creating a cohesive data strategy is challenging
(no registration required)
About Medrio:
Trusted by sponsors, CROs and sites worldwide, Medrio (www.medrio.com) aims to improve 100 million lives through faster, more efficient, and secure clinical trials. With almost two decades of experience, Medrio delivers proven, scalable solutions, unrivaled customer support, and guidance to the industry’s leading innovators, including pharmaceutical, biotech, medical device, diagnostics and more.
The company’s suite of solutions, including CDMS/EDC, eCOA/ePRO, eConsent, and RTSM, enables the capture of quality clinical trial data while optimizing workflows for regulatory readiness. Experience the power of Medrio and realize the full potential of your clinical operations and outcomes.